Market revenue in 2022 | USD 1,892.7 million |
Market revenue in 2030 | USD 2,409.1 million |
Growth rate | 3.1% (CAGR from 2022 to 2030) |
Largest segment | Branded |
Fastest growing segment | Generics |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Branded, Generics |
Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 68.22% in 2022. Horizon Databook has segmented the Canada gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2018 to 2030.
Gastrointestinal therapeutics market in Canada is expected to witness lucrative growth, owing to the high prevalence of gastrointestinal disorders, such as Gastroesophageal Reflux Disease (GERD) and Irritable Bowel Syndrome (IBS).
Furthermore, increasing penetration of key players with novel drugs is anticipated to support the country’s growth in the coming years. For instance, in January 2020, Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, gained Health Canada approval for STELARA for the treatment of moderately to severely active ulcerative colitis in adult patients.
Various emerging players are undertaking strategic initiatives, such as mergers and acquisitions, to expand their therapeutics portfolio. For instance, in December 2016, Knight Therapeutics Inc., a Canada-based specialty pharmaceutical company, gained the exclusive license to market and sell MOVANTIK in Canada and Israel from AstraZeneca plc.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Canada gastrointestinal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account